Adma stock forecast consensus ADMA stock forecast remains

Consensus ADMA stock forecast remains positive for 12-month outlook, bolstered by strong fundamentals, product demand, and healthy sector performance. Kevin Mahn, President & CIO at Hennion & Walsh Asset Management, recently appeared on CNBC on January 6 to discuss the current market momentum and emphasize the need for investors to be selective in 2025 to find growth opportunities. He highlighted that while the MAG7 have led the market recently, their leadership may not continue. Mahn referenced historical data, noting that since 1950, there have been nine instances where the market rallied by 20% or more, with the market rising in eight of those cases. However, he pointed out that gains in the following year averaged only 3.6%, indicating a need for careful selection. He also acknowledged recent market trends, including a decline in the S&P 500's performance and a potential shift in investor sentiment following events like the Santa Claus Rally. It's only 1/9,000th the size of NVIDIA which skyrocketed more than +800% since we recommended it. NVIDIA is still strong, but our new top chip stock has much more room to boom. Analyst consensus for ADMA stock forecast in 2024 sets target range $8-$9, reflecting ongoing demand for niche plasma-derived therapies and stable cash flows.